Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Sartorius Stedim Biotech is experiencing significant volatility in the life sciences industry, with the company guiding flat growth as customers reduce inventories and remain reluctant to invest. The company reported a 16% drop in earnings, reflecting the mixed picture and lack of stable positive momentum in the industry. Sartorius highlighted increased uncertainties due to geopolitical changes and emerging decoupling tendencies among various countries. Despite some positive momentum in their consumables business and solutions for cell and gene therapies, overall customer demand remains muted, particularly in China. Sartorius Stedim Biotech's stock fell 15% today.
Sartorius Stedim Biotech: "While parts of our consumables business as well as our solutions for cell and gene therapies show positive momentum, customer demand for other product groups remains muted, as do market dynamics in China" -15% today https://t.co/lbBTvHKuNj
$DIM Sartorius Stedim: "...dynamics and volatilities in the industry have increased significantly in recent years." "...uncertainties due to the changed geopolitical situation, such as the emerging decoupling tendencies of various countries, are playing a greater role." https://t.co/GPEizbBDXH
$DIM Sartorius: "The life science industry continues to show a mixed picture with no stable positive momentum." https://t.co/0wnBXPIWTb